Company Profile

NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisense oligonucleotide (PATrOL™) platform to address genetic diseases caused by mutant proteins with a single, cohesive approach. The systemically-deliverable PATrOL therapies have the potential to improve upon current gene silencing treatments by combining the advantages of synthetic approaches with the precision of antisense technologies. NeuBase intends to use its platform to address repeat expansion disorders, with an initial focus on Huntington’s disease and myotonic dystrophy, as well as a variety of other genetic disorders.


Contact Information

Investor Relations
LifeSci Advisors, LLC
Dan Ferry
1 International Place
14th Floor
Boston, MA 02110
T: 617-535-7746

Company Contact
NeuBase Therapeutics, Inc.
350 Technology Drive
Pittsburgh, PA 15219
T: 646-450-1790